Dyne Therapeutics (Nasdaq:DYN) granted inducement equity awards to six new employees under Nasdaq Listing Rule 5635(c)(4). Awards include non-statutory stock options for up to 126,000 shares and 40,100 restricted stock units, granted under Dyne’s 2024 Inducement Stock Incentive Plan.
Options have a ten-year term and vest over four years, while RSUs vest in four equal annual installments, all subject to continued service.
Loading...
Loading translation...
Positive
None.
Negative
None.
News Market Reaction – DYN
+5.40%
5 alerts
+5.40%News Effect
+$173MValuation Impact
$3.39BMarket Cap
0.2xRel. Volume
On the day this news was published, DYN gained 5.40%, reflecting a notable positive market reaction.
Our momentum scanner triggered 5 alerts that day, indicating moderate trading interest and price volatility.
This price movement added approximately $173M to the company's valuation, bringing the market cap to $3.39B at that time.
The stock moved +5.4% in the session following this news. A strong positive reaction aligns with Dyn...
Analysis
The stock moved +5.4% in the session following this news. A strong positive reaction aligns with Dyne’s history of upbeat responses to corporate developments, though elevated short positioning around 22% of float suggests any sharp gains could be vulnerable to reversals if sentiment cools.
Key Figures
New hires:6 employeesStock options granted:126,000 sharesRSUs granted:40,100 shares+5 more
8 metrics
New hires6 employeesInducement equity awards June 2026
Stock options granted126,000 sharesInducement non-statutory options June 16, 2026 grant
RSUs granted40,100 sharesInducement restricted stock units June 2026
Initiated global Phase 3 FORZETTO trial of z-rostudirsen in DMD.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Pattern Detected
Recent Dyne news has typically driven positive price reactions, especially around clinical and financing milestones, with only a small divergence on routine equity grant news.
"inducement equity awards to 6 newly hired employees... in accordance with Nasdaq Listing Rule 5635(c)(4)"
NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.
non-statutory stock optionsfinancial
"The inducement equity awards consisted of non-statutory stock options to purchase up to an aggregate of 126,000 shares"
Non-statutory stock options are a type of reward that companies give to employees, allowing them to buy company shares at a set price within a certain period. Unlike formal or government-approved plans, these options are more flexible but may have different tax implications. For investors, they can influence a company's stock price and financial health, making them an important factor to consider.
restricted stock unitsfinancial
"and restricted stock units with respect to an aggregate of 40,100 shares of Dyne’s common stock"
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
inducement stock incentive planfinancial
"subject to the terms and conditions of... Dyne’s 2024 Inducement Stock Incentive Plan"
An inducement stock incentive plan is a program that gives newly hired employees or executives shares or stock-based awards as a reward for joining a company and to encourage them to stay and perform. For investors, it matters because these grants can dilute existing shareholders, increase reported compensation costs, and signal how a company is investing in talent—similar to a signing bonus mixed with a stake in the business.
WALTHAM, Mass., June 18, 2026 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases, today announced that it has granted inducement equity awards to 6 newly hired employees. The awards were made as an inducement material to the newly hired employees’ acceptance of employment with Dyne in accordance with Nasdaq Listing Rule 5635(c)(4).
The inducement equity awards consisted of non-statutory stock options to purchase up to an aggregate of 126,000 shares of Dyne’s common stock at a per share exercise price equal to the closing price of Dyne’s common stock on The Nasdaq Global Select Market on June 16, 2026, and restricted stock units with respect to an aggregate of 40,100 shares of Dyne’s common stock. The stock options have a ten-year term and are scheduled to vest over four years, with 25% of the original number of shares vesting on the first anniversary of the applicable employee’s start date and the remainder vesting in 12 equal quarterly installments thereafter, subject to such employee’s continued service to Dyne through the applicable vesting dates. The restricted stock units are scheduled to vest over four years from the applicable employee’s start date in four equal annual installments, subject to such employee’s continued service to Dyne through the applicable vesting dates.
The inducement equity awards are subject to the terms and conditions of award agreements covering the grants and Dyne’s 2024 Inducement Stock Incentive Plan.
About Dyne Therapeutics
Dyne Therapeutics is focused on delivering functional improvement for people living with genetically driven neuromuscular diseases. We are developing therapeutics that target muscle and the central nervous system (CNS) to address the root cause of disease. The company is advancing clinical programs for Duchenne muscular dystrophy (DMD) and myotonic dystrophy type 1 (DM1) as well as preclinical programs for facioscapulohumeral muscular dystrophy (FSHD), Pompe disease and multiple DMD mutations. At Dyne, we are on a mission to deliver functional improvement for individuals, families and communities. Learn more at https://www.dyne-tx.com/, and follow us on X, LinkedIn and Facebook.
Contacts: Investors Mia Tobias ir@dyne-tx.com 781-317-0353
What inducement equity awards did Dyne Therapeutics (DYN) grant on June 18, 2026?
Dyne Therapeutics granted stock options and restricted stock units as inducement awards to six new employees. According to Dyne, these include options for up to 126,000 shares and 40,100 RSUs, issued under its 2024 Inducement Stock Incentive Plan.
How many Dyne Therapeutics (DYN) shares are covered by the new employee stock options?
The inducement stock options cover up to an aggregate of 126,000 Dyne common shares. According to Dyne, the exercise price equals the June 16, 2026 Nasdaq Global Select Market closing price, and the options have a ten-year term with four-year vesting.
What are the vesting terms for Dyne Therapeutics (DYN) inducement stock options granted in June 2026?
Dyne’s inducement stock options vest over four years, subject to continued service. According to Dyne, 25% vests on the first anniversary of each employee’s start date, with the remaining 75% vesting in 12 equal quarterly installments thereafter.
How do Dyne Therapeutics (DYN) inducement restricted stock units vest for new hires?
The inducement RSUs vest over four years from each employee’s start date. According to Dyne, vesting occurs in four equal annual installments, and each installment is contingent on the employee’s continued service through the applicable vesting date.
Under which plan were Dyne Therapeutics (DYN) June 2026 inducement grants issued?
The June 2026 inducement equity awards were issued under Dyne’s 2024 Inducement Stock Incentive Plan. According to Dyne, the grants are also governed by individual award agreements specifying terms and vesting conditions tied to continued employment.
Why did Dyne Therapeutics (DYN) use Nasdaq Listing Rule 5635(c)(4) for these equity grants?
Dyne used Nasdaq Listing Rule 5635(c)(4) to grant equity as a material inducement to new hires. According to Dyne, the awards were made as a condition of accepting employment and are structured as non-statutory options and RSUs with multi-year vesting.
